Free Trial
→ Every Starlink dish pays this stock (From Behind the Markets) (Ad)tc pixel
OTCMKTS:MKKGY

Merck KGaA Q1 2026 Earnings Results & Report

Merck KGaA logo
$32.62 -1.22 (-3.61%)
As of 03:58 PM Eastern

Merck KGaA beat analyst expectations on both earnings and revenue in its Q1 2026 results, released May 13, 2026. The company reported EPS of $0.59 versus the $0.45 consensus estimate, while revenue of $6.03 billion topped the $5.93 billion estimate by $90.91 million.

Research:ProfileEarnings HistoryForecast

Earnings Announcement Details

Quarter
Q1 2026
Report Date
Time
Before Market Opens

Merck KGaA EPS Results

Actual EPS
$0.59
Consensus EPS
$0.45
Beat/Miss
Beat by +$0.14
One Year Ago EPS
N/A
EPS Beat Rate
5 of last 8 quarters

Merck KGaA Revenue Results

Actual Revenue
$6.03 billion
Expected Revenue
$5.93 billion
Beat/Miss
Beat by +$90.91 million
YoY Revenue Growth
N/A

Upcoming Earnings

Merck KGaA's next earnings date is estimated for Thursday, November 12, 2026, based on past reporting schedules.

Conference Call Resources

Merck KGaA Q1 2026 Earnings FAQ

Merck KGaA (OTCMKTS:MKKGY) reported earnings of $0.59 per share for Q1 2026, beating the consensus estimate of $0.45. The report was announced on Wednesday, May 13, 2026.

Merck KGaA reported revenue of $6.03 billion for Q1 2026, against a consensus estimate of $5.93 billion.

Merck KGaA's next earnings date is estimated for Thursday, November 12, 2026. MarketBeat tracks confirmed and estimated earnings dates for Merck KGaA on the company's earnings history page.

Merck KGaA Earnings Headlines

Merck KGaA puts its shareholders' patience to the test
 |  marketscreener.comM
Merck KGaA (MKKGY) lags Q3 earnings estimates
November 12 at 12:24 PM  |  msn.comhttps://www.msn.com/en-us/money/economy/merck-kgaa-mkkgy-lags-q3-earnings-estimates/ar-AA2hisEb
My public warning after 55 years of watching the markets
Dr. Martin D. Weiss has publicly predicted six major American market crashes over his 55-year career, each warning issued before the crisis hit. Now the founder of Weiss Ratings, the only conflict-free rating agency in America, says he is watching a $3 trillion problem that could trigger a chain reaction across markets and banks.tc pixel
November 12 at 1:00 AM  |  Weiss Ratings (Ad)
Merck KGaA raises 2026 outlook as Bio-Techne deal nears completion
November 12 at 12:24 PM  |  seekingalpha.comhttps://seekingalpha.com/news/4671547-merck-kgaa-raises-2026-outlook-bio-techne-deal
Merck KGaA Lifts Outlook Again on Life Science Strength
November 12 at 7:24 AM  |  bloomberg.comhttps://www.bloomberg.com/news/articles/2026-11-12/merck-kgaa-lifts-outlook-again-on-life-science-strength
RBC Upbeat on Lonza's CDMO Deal with Merck KGaA; Forecasts Updated
November 5, 2026  |  marketscreener.comM
See More Merck KGaA Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Merck KGaA? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Merck KGaA and other key companies, straight to your email.

About Merck KGaA

Merck KGaA (OTCMKTS:MKKGY) is a German science and technology company headquartered in Darmstadt. Founded in 1668, it traces its origins to a pharmacy established by the Merck family and has grown into a global business serving customers in healthcare, research and industry. It is separate from the U.S.-based Merck & Co.

The company operates through three main businesses. Its Healthcare division develops and markets prescription medicines, including treatments in areas such as oncology, neurology and fertility. Life Science supplies laboratory products, research tools and services, as well as materials and technologies used in pharmaceutical manufacturing.

Through its Electronics division, Merck provides specialty materials and solutions for the semiconductor and display industries. The company serves customers internationally, with operations and markets spanning numerous regions around the world.

View Merck KGaA Profile
Earnings Tools